A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder

Autor/inn/en	Wink, Logan K.; Adams, Ryan; Horn, Paul S.; Tessier, Charles R.; Bantel, Andrew P.; Hong, Michael; Shaffer, Rebecca C.; Pedapati, Ernest V.; Erickson, Craig A.
Titel	A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder
Quelle	In: Journal of Autism and Developmental Disorders, 48 (2018) 9, S.3051-3060 (10 Seiten) PDF als Volltext Verfügbarkeit
Zusatzinformation	ORCID (Wink, Logan K.)
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0162-3257
DOI	10.1007/s10803-018-3562-5
Schlagwörter	Drug Therapy; Autism; Pervasive Developmental Disorders; Safety; Outcomes of Treatment; Symptoms (Individual Disorders); Check Lists; Randomized Controlled Trials + Suchen Sie Ihr Suchwort? Autismus; Sicherheit; Psychiatrische Symptomatik; Checkliste
Abstract	Riluzole is a glutamatergic modulator of particular interest in autism spectrum disorder (ASD). In this 12-week randomized, double-blind, placebo-controlled, crossover pilot study we evaluated the safety and tolerability of 5-week of adjunctive riluzole treatment (vs. 5-week of placebo, with 2-week washout period) targeting ASD-associated drug-refractory irritability in eight individuals age 12-25 years. All participants tolerated riluzole 200 mg per day, however there were no statistically significant findings for the overall treatment effect, the treatment effect by week within period of the study, or a cross-over effect across the periods of the study on the Clinical Global Impression Improvement Scale or the Aberrant Behavior Checklist Irritability subscale. The results of this trial indicate that 5-week of riluzole treatment was well tolerated, but had no significant effect on the target symptoms. "Trial Registration" ClinicalTrials.gov Identifier NCT02081027, Registered 5 August 2013, First participant enrolled 19 September 2013. (As Provided).
Anmerkungen	Springer. Available from: Springer Nature. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: customerservice@springernature.com; Web site: https://link.springer.com/
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2020/1/01